(Q33847825)

29 July 2017

Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha (English)

1 reference

29 July 2017

1 reference

1 reference

S Yang

1

1 reference

29 July 2017

P de Souza

series ordinal

2

1 reference

29 July 2017

E Alemao

series ordinal

3

1 reference

29 July 2017

J Purvis

series ordinal

4

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

British Journal of Cancer

29 July 2017

1 reference

29 July 2017

102

1 reference

29 July 2017

10

1 reference

29 July 2017

1456-1460

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605647

29 July 2017

0 references

cites work

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869160

Targeted therapy for advanced renal cell carcinoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869160

28 July 2018

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869160

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869160

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869160

Renal-cell carcinoma--molecular pathways and therapies.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869160

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869160

Novel treatment strategies in clear-cell metastatic renal cell carcinoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869160

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869160

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869160

EuroQol--a new facility for the measurement of health-related quality of life

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869160

Statistical analysis of repeated measures data using SAS procedures

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869160

Modeling valuations for EuroQol health states

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869160

EuroQol: the current state of play

28 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605647

Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605647

Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605647

Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605647

Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605647

Global increases in kidney cancer incidence, 1973-1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605647

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605647

Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2869160

Interpreting clinically significant changes in patient-reported outcomes

29 October 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605647

A single European currency for EQ-5D health states

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20461090

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20461090

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/SJ.BJC.6605647

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference